Sprout Pharmaceuticals, Inc.
Sprout Pharmaceuticals is a private Raleigh-based pharma company that markets Addyi (flibanserin), the only FDA-approved non-hormonal pill for hypoactive sexual desire disorder in premenopausal and postmenopausal women under 65, sold direct-to-consumer via specialty pharmacy and telemedicine channels.
- Company typePrivate
- Founded2015
- HeadquartersRaleigh, United States
- Headcount—
- GTM typeB2C
- OfferingHardware or Manufacturing
What Sprout Pharmaceuticals, Inc. does
Sprout Pharmaceuticals, Inc. is a privately held, Raleigh, North Carolina-based specialty pharmaceutical company that develops and commercializes Addyi (flibanserin 100mg), the only FDA-approved non-hormonal medication for hypoactive sexual desire disorder (HSDD) in women under 65. Addyi is a once-daily bedtime oral tablet that modulates brain neurotransmitter activity (dopamine, norepinephrine, and serotonin pathways via 5-HT1A agonism and 5-HT2A antagonism) to treat acquired, generalized HSDD. The product received initial FDA approval in 2015 for premenopausal women and gained an expanded indication in December 2025 to include naturally postmenopausal women under 65, roughly doubling the addressable population. Clinical efficacy has been demonstrated in four six-month trials covering over 3,200 women, with statistically significant improvements in satisfying sexual events, desire scores, and distress measures versus placebo.
The company operates a direct-to-consumer commercial model anchored by three channel partners: PhilRx as the exclusive specialty pharmacy (with automatic coupon application and home delivery), BeyondMD as the telemedicine front door, and GoodRx for retail pharmacy coupon access. Pricing is structured at as little as $20/month for commercially insured patients and $149/month for cash-pay patients through PhilRx, with a $19-$49 telemedicine consultation fee. The company employs a hybrid go-to-market combining direct-to-consumer digital marketing (addyi.com, HSDD awareness content, patient testimonials, screening quiz) with healthcare provider outreach to OB/GYNs, family medicine physicians, internists, and nurse practitioners through a dedicated provider portal (addyihcp.com). Six U.S. patents protect the flibanserin formulation, and the ADDYI trademark is registered. Revenue, funding, ownership, and headcount data are not disclosed in available sources.
Sprout Pharmaceuticals, Inc. firmographics
Firmographics- Name
- Sprout Pharmaceuticals, Inc.
- Legal name
- Sprout Pharmaceuticals, Inc.
- Website
- https://addyi.com
- Company type
- Private
- Founded year
- 2015
- Operating status
- Operating
- Short description
- Sprout Pharmaceuticals is a private Raleigh-based pharma company that markets Addyi (flibanserin), the only FDA-approved non-hormonal pill for hypoactive sexual desire disorder in premenopausal and postmenopausal women under 65, sold direct-to-consumer via specialty pharmacy and telemedicine channels.
- Ownership category
- akta.pro rank
Sprout Pharmaceuticals, Inc. industry classification
Industry- Product category
- Women's Sexual Health Pharmaceuticals (HSDD Treatment)
- NAICS
- Scientific Research and Development Services (5417)
- SIC
- Pharmaceutical Preparations (2834)
- akta.pro primary industry
- Endocrinology & Reproductive Health Pharmaceuticals (incl. Women’s Health) (HLAIAAAJ)
Keywords
Where Sprout Pharmaceuticals, Inc. is headquartered
LocationHeadquarters
- HQ city
- Raleigh
- HQ country
- United States
- HQ region
- North America
Offices1 record
Markets served
Sprout Pharmaceuticals, Inc. business model
Business model- GTM type
- B2C
- Offering type
- Hardware or Manufacturing
- Cost components
- Personnel, Marketing or Sales, Technology or R&D, Supply Chain, Operations, Others
Revenue model
- Prescription pharmaceutical sales: Sprout Pharmaceuticals generates revenue through sales of Addyi (flibanserin 100mg), a prescription-only medication. Revenue flows through specialty pharmacy (PhilRx) for insured patients and cash-paying customers. Patients with commercial insurance pay as little as $20/month or $40/year through PhilRx. Cash-paying patients pay $149/month through PhilRx with free home delivery. The company also offers GoodRx coupons for local pharmacy pickup at approximately $20/month for eligible patients.
Pricing tiers
| Model | Billing | Price |
|---|---|---|
| Subscription | Monthly | Commercial insurance patients through PhilRx: as low as $20/month |
| Subscription | Annual | Commercial insurance through PhilRx: $40/year |
| Subscription | Monthly | Cash-paying patients through PhilRx: $149/month |
| Subscription | Monthly | GoodRx coupon for local pharmacy pickup: as low as $20/month |
| Other | Pay-as-you-go | Telemedicine online visit: $19-$49 |
Go-to-market motion2 records
Distribution channels4 records
Marketing channels6 records
Sprout Pharmaceuticals, Inc. product offering
Product offeringCore offering
Sprout Pharmaceuticals develops and sells Addyi (flibanserin 100mg), the only FDA-approved non-hormonal once-daily oral prescription medication indicated for the treatment of hypoactive sexual desire disorder (HSDD) in women under 65 years of age, covering both premenopausal and postmenopausal populations. The drug works by rebalancing brain neurotransmitters (dopamine, norepinephrine, serotonin) associated with sexual desire, and is dispensed primarily through the company's exclusive specialty pharmacy partner PhilRx, supported by telemedicine evaluations via BeyondMD and GoodRx coupon access at retail pharmacies.
Product overview
Sprout Pharmaceuticals offers a single pharmaceutical product, Addyi (flibanserin), which is the only FDA-approved treatment for hypoactive sexual desire disorder (HSDD) in premenopausal and postmenopausal women under 65. Addyi is available as a 100mg pink oval tablet taken once daily at bedtime. The company partners with specialty pharmacies (PhilRx) and telemedicine providers (BeyondMD) for prescription fulfillment and patient consultations.
Differentiator
Problem solved
Functional benefit
Products and services
- Addyi (flibanserin) 100mg tablets Addyi is a once-daily, 100mg pink oval film-coated oral tablet (debossed 'f100') taken at bedtime, indicated for the treatment of acquired, generalized hypoactive sexual desire disorder (HSDD) in women under 65 years of age. It is the only FDA-approved non-hormonal pharmacological treatment for HSDD, working by rebalancing brain neurotransmitters (dopamine, norepinephrine, serotonin) related to sexual desire, with effects typically assessable at 8 weeks. Dispensed via prescription through PhilRx specialty pharmacy (with GoodRx coupon alternative at retail pharmacies) after evaluation by a licensed prescriber (in-person or via BeyondMD telemedicine).
Quantifiable outcome
- In clinical trials, ADDYI-treated patients experienced significantly more satisfying sexual events (SSEs) compared to placebo. Study 3: +2.5 SSEs vs +1.5 for placebo (p<0.0001).
- +2 more outcomes
Companies that use Sprout Pharmaceuticals, Inc.
Customer profileNamed customers8 records
Segments3 records
Ideal customer profiles2 records
Sprout Pharmaceuticals, Inc. technology and API
TechnologyTechnology focussed No
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Feature3 records
Sprout Pharmaceuticals, Inc. partnerships and signals
Strategic signalPartnerships
Three partnerships are on record, tiered core and minor.
- PhilRxcorePhilRx serves as the exclusive specialty pharmacy partner for Addyi distribution. They automatically apply copay coupons for insured patients, offer $149/month cash pricing with free shipping, and provide prior authorization (PA) support. Prescribers search 'PHILRX' in EMR pharmacy finders or contact them directly at (855) 977-0975 for address 150 E. Campus View Blvd, Suite 210, Columbus OH 43235.
- GoodRxminorGoodRx provides discount coupons for Addyi at local retail pharmacies. Patients can access pricing as low as $20/month through GoodRx and present coupons at their local pharmacy of choice, offering an alternative to PhilRx mail-order delivery.
- BeyondMDcoreBeyondMD is the third-party telemedicine provider enabling online consultations for Addyi. Patients complete health questionnaires through addyi.com and connect with licensed healthcare providers in their state for $19-$49 consultations. If appropriate, providers write prescriptions which can be sent to PhilRx or picked up locally with GoodRx coupons.
Scale indicators3 records
Recent moves6 records
Expansion highlights5 records
Sprout Pharmaceuticals, Inc. competitors and assessment
Company assessmentEmerging players
- Materna: Materna is a smaller specialty pharma/consumer health company operating in women's intimate wellness, overlapping with Sprout's patient population though with non-prescription offerings.
- Duchesnay: Duchesnay is a specialty women's health pharmaceutical company focused on pregnancy and menopause products, making it an emerging player with overlapping therapeutic categories and prescriber channels.
- Evofem Biosciences: Evofem is a women's sexual and reproductive health company (Phexxi), focused on underserved female indications, making it a smaller emerging player comparable in therapeutic niche focus to Sprout.
- Bonafide Health: Bonafide Health is a consumer-focused women's health company selling proprietary, non-prescription products for menopause and sexual wellness, representing an adjacent emerging competitor addressing similar patient demand.
Broad incumbents
- Bayer (Women's Health): Bayer operates a large women's healthcare franchise including contraception and menopause therapies, addressing overlapping patient populations and prescriber specialties (OB/GYN) targeted by Sprout's Addyi commercial effort.
- Pfizer: Pfizer is a major pharmaceutical company with a historical connection to flibanserin's development and broad women's health and CNS franchises, serving as a broad incumbent with potential competitive or partnership relevance to Sprout.
- AbbVie: AbbVie markets women's health products (e.g., Lo Loestrin, Orilissa, Oriahnn) and engages the same OB/GYN and primary-care prescriber audience as Sprout, serving as a broad incumbent in branded women's health pharma.
- TherapeuticsMD (now Mayne Pharma): TherapeuticsMD/Mayne Pharma is a specialty women's health pharmaceutical company with prescription products in menopause and reproductive health, overlapping with Sprout's focus on FDA-approved women's health therapeutics.
- Organon & Co. Organon is a global women's health-focused pharmaceutical company (spun from Merck) with a portfolio across contraception, fertility, and menopause, making it a broad incumbent serving similar HCPs and patient demographics as Sprout.
Direct peers
- Palatin Technologies: Palatin developed and markets Vyleesi (bremelanotide), the only other FDA-approved treatment for HSDD in premenopausal women, making it a direct competitor to Sprout's Addyi in the same indication and prescriber base.
Market position
Strengths5 records
Weaknesses5 records
Competitive moat4 records
Key risks6 records
Key highlights6 records
Customer concentration
Sprout Pharmaceuticals, Inc. financial estimates
Financial estimateRevenue estimate
Valuation estimate
Sprout Pharmaceuticals, Inc. leadership team
Management profileNumber of profiles
Sprout Pharmaceuticals, Inc. funding detail
Funding detailFunding overview
Funding rounds
Investors
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
Sprout Pharmaceuticals, Inc. M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about Sprout Pharmaceuticals, Inc.
What does Sprout Pharmaceuticals, Inc. do?
Sprout Pharmaceuticals develops and sells Addyi (flibanserin 100mg), the only FDA-approved non-hormonal once-daily oral prescription medication indicated for the treatment of hypoactive sexual desire disorder (HSDD) in women under 65 years of age, covering both premenopausal and postmenopausal populations. The drug works by rebalancing brain neurotransmitters (dopamine, norepinephrine, serotonin) associated with sexual desire, and is dispensed primarily through the company's exclusive specialty pharmacy partner PhilRx, supported by telemedicine evaluations via BeyondMD and GoodRx coupon access at retail pharmacies.
Is Sprout Pharmaceuticals, Inc. a public or private company?
Sprout Pharmaceuticals, Inc. is a private company. It is classified as unknown and is currently operating.
When was Sprout Pharmaceuticals, Inc. founded?
Sprout Pharmaceuticals, Inc. was founded in 2015.
Where is Sprout Pharmaceuticals, Inc. based?
Sprout Pharmaceuticals, Inc. is headquartered in Raleigh, United States, in the North America region.
How does Sprout Pharmaceuticals, Inc. make money?
One revenue line is on record: prescription pharmaceutical sales.
Who are Sprout Pharmaceuticals, Inc.'s main competitors?
Emerging players on record are Materna, Duchesnay, Evofem Biosciences and Bonafide Health. Broad incumbents are Bayer (Women's Health), Pfizer, AbbVie, TherapeuticsMD (now Mayne Pharma) and Organon & Co.. Palatin Technologies is listed as a direct peer.
Does Sprout Pharmaceuticals, Inc. have an API?
No public API is recorded for Sprout Pharmaceuticals, Inc..
What industry is Sprout Pharmaceuticals, Inc. in?
Sprout Pharmaceuticals, Inc.'s product category is Women's Sexual Health Pharmaceuticals (HSDD Treatment). Its primary akta.pro industry code is HLAIAAAJ, Endocrinology & Reproductive Health Pharmaceuticals (incl. Women’s Health). Its NAICS code is 5417 and its SIC code is 2834.